A database of antimalarial drug resistance

A large investment is required to develop, license and deploy a new antimalarial drug. Too often, that investment has been rapidly devalued by the selection of parasite populations resistant to the drug action. To understand the mechanisms of selection, detailed information on the patterns of drug use in a variety of environments, and the geographic and temporal patterns of resistance is needed. Currently, there is no publically-accessible central database that contains information on the levels of resistance to antimalaria drugs.This paper outlines the resources that are available and the steps that might be taken to create a dynamic, open access database that would include current and historical data on clinical efficacy, in vitro responses and molecular markers related to drug resistance in Plasmodium falciparum and Plasmodium vivax. The goal is to include historical and current data on resistance to commonly used drugs, like chloroquine and sulfadoxine-pyrimethamine, and on the many combinations that are now being tested in different settings. The database will be accessible to all on the Web.The information in such a database will inform optimal utilization of current drugs and sustain the longest possible therapeutic life of newly introduced drugs and combinations. The database will protect the valuable investment represented by the development and deployment of novel therapies for malaria.

[1]  M. Duraisingh,et al.  Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. , 1998, Experimental parasitology.

[2]  B. Karoumi,et al.  Vitamin therapy and prevention of neural tube defects , 2001 .

[3]  S. Lamola,et al.  Relationship between age, molecular markers, and response to sulphadoxine–pyrimethamine treatment in Kampala, Uganda , 2004, Tropical medicine & international health : TM & IH.

[4]  R. Snow,et al.  Using evidence to change antimalarial drug policy in Kenya , 2000, Tropical medicine & international health : TM & IH.

[5]  I. Hastings.  The origins of antimalarial drug resistance. , 2004, Trends in parasitology.

[6]  J. Kublin,et al.  Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. , 2003, The Journal of infectious diseases.

[7]  F. Nosten,et al.  A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand , 2005, Malaria Journal.

[8]  C. Gamble,et al.  Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. , 2006, The Cochrane database of systematic reviews.

[9]  C. Plowe,et al.  Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. , 2002, The Journal of infectious diseases.

[10]  N. White,et al.  Delaying antimalarial drug resistance with combination chemotherapy. , 1999, Parassitologia.

[11]  W. Wernsdorfer,et al.  Declining mefloquine sensitivity of Plasmodium falciparum along the Thai-Myanmar border. , 2004, The Southeast Asian journal of tropical medicine and public health.

[12]  H. Myint,et al.  A systematic overview of published antimalarial drug trials. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[13]  B. Sharp,et al.  Intercontinental Spread of Pyrimethamine-Resistant Malaria , 2004, Science.

[14]  C. Drakeley,et al.  Molecular Determination of Point Mutation Haplotypes in the Dihydrofolate Reductase and Dihydropteroate Synthase of Plasmodium falciparum in Three Districts of Northern Tanzania , 2003, Antimicrobial Agents and Chemotherapy.

[15]  B. Sharp,et al.  Antifolate antimalarial resistance in southeast Africa: a population-based analysis , 2003, The Lancet.

[16]  M. Thomson,et al.  Mapping malaria risk in Africa: What can satellite data contribute? , 1997, Parasitology today.

[17]  S. Donegan,et al.  Chemoprophylaxis and intermittent treatment for preventing malaria in children. , 2008, The Cochrane database of systematic reviews.

[18]  P. Garner,et al.  Drugs for treating uncomplicated malaria in pregnant women. , 2005, The Cochrane database of systematic reviews.

[19]  François Nosten,et al.  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number , 2004, The Lancet.

[20]  D. Warhurst,et al.  The chemotherapy of rodent malaria. XLIV. Studies on the mode of action of CM 6606, an indolo (3,2-c) quinoline N-oxide. , 1989, Annals of tropical medicine and parasitology.

[21]  H. Babiker,et al.  Fitness of drug-resistant malaria parasites. , 2005, Acta tropica.

[22]  J. Trape.  The public health impact of chloroquine resistance in Africa. , 2001, The American journal of tropical medicine and hygiene.

[23]  S. Meshnick,et al.  A new method for detection of pfmdr1 mutations in Plasmodium falciparum DNA using real-time PCR , 2004, Malaria Journal.

[24]  R. Snow,et al.  The past, present and future of childhood malaria mortality in Africa. , 2001, Trends in parasitology.

[25]  P. Newton,et al.  A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. , 2003, Molecular biology and evolution.

[26]  S. Krishna,et al.  Artemisinins target the SERCA of Plasmodium falciparum , 2003, Nature.

[27]  H. Noedl.  Artemisinin resistance: how can we find it? , 2005, Trends in parasitology.

[28]  L. Stewart,et al.  The chemotherapy of rodent malaria. LXIII. Drug combinations to impede the selection of drug resistance, part 6: the potential value of chlorproguanil and dapsone in combination, and with the addition of artesunate , 2005, Annals of tropical medicine and parasitology.

[29]  P. Rosenthal,et al.  Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. , 2003, The American journal of tropical medicine and hygiene.

[30]  C. Plowe.  Monitoring antimalarial drug resistance: making the most of the tools at hand , 2003, Journal of Experimental Biology.

[31]  S. Meshnick,et al.  Real-time PCR methods for monitoring antimalarial drug resistance. , 2005, Trends in parasitology.

[32]  M. Pai,et al.  Chloroquine or amodiaquine combined with sulfadoxine–pyrimethamine for uncomplicated malaria: a systematic review , 2006, Tropical medicine & international health : TM & IH.

[33]  U. d’Alessandro,et al.  Monitoring antimalarial drug resistance (report of a WHO Consultation) , 2001 .

[34]  Jonathan E. Allen,et al.  Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii , 2002, Nature.

[35]  I. Sim,et al.  Beyond Trial Registration: A Global Trial Bank for Clinical Trial Reporting , 2005, PLoS medicine.

[36]  T. Ruebush,et al.  Practical aspects of in vivo antimalarial drug efficacy testing in the Americas. , 2003, The American journal of tropical medicine and hygiene.

[37]  T. Q. Toan,et al.  Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: a study in vivo and in vitro. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[38]  F. Nosten,et al.  Rapid genotyping of loci involved in antifolate drug resistance in Plasmodium falciparum by primer extension. , 2002, International journal for parasitology.

[39]  R. Snow,et al.  A preliminary continental risk map for malaria mortality among African children. , 1999, Parasitology today.

[40]  L. Corey,et al.  The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub‐regional policy , 2003, Tropical medicine & international health : TM & IH.

[41]  E. Kamau.  Field-derived research materials in the African region: challenges and opportunities for the malaria researcher. , 2005, Acta tropica.

[42]  A. Cowman,et al.  Chemotherapy and drug resistance in malaria. , 1990, International journal for parasitology.

[43]  Kenneth J. Arrow,et al.  Saving lives, buying time : economics of malaria drugs in an age of resistance , 2004 .

[44]  J. Baird,et al.  Chloroquine Resistance in Plasmodium vivax , 2004, Antimicrobial Agents and Chemotherapy.

[45]  C. Plowe.  Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. , 2005, Current topics in microbiology and immunology.

[46]  D. Warhurst.  A molecular marker for chloroquine-resistant falciparum malaria. , 2001, The New England journal of medicine.

[47]  P. Rosenthal,et al.  Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. , 2005, The American journal of tropical medicine and hygiene.

[48]  R. Price,et al.  In Vivo Assessment of Drug Efficacy against Plasmodium falciparum Malaria: Duration of Follow-Up , 2004, Antimicrobial Agents and Chemotherapy.

[49]  P. Bloland,et al.  Combination therapy for malaria in Africa: hype or hope? , 2000, Bulletin of the World Health Organization.

[50]  A. Nzila,et al.  The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. , 2000, The American journal of tropical medicine and hygiene.

[51]  John C. Wootton,et al.  Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum , 2002, Nature.

[52]  C. Wongsrichanalai,et al.  Malaria drug-sensitivity testing: new assays, new perspectives. , 2003, Trends in parasitology.

[53]  J. Carlton,et al.  Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum. , 2001, Current opinion in microbiology.

[54]  J. Kublin,et al.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. , 2002, The Journal of infectious diseases.

[55]  S. Meshnick,et al.  pfmdr1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border. , 2005, The American journal of tropical medicine and hygiene.

[56]  C. Gamble,et al.  Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. , 2005, The Cochrane database of systematic reviews.

[57]  R. Price,et al.  Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[58]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[59]  O. Doumbo,et al.  Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria , 2001, The Lancet.

[60]  J. Baird,et al.  Effectiveness of antimalarial drugs. , 2005, The New England journal of medicine.

[61]  X. Su,et al.  Dissecting the loci of low‐level quinine resistance in malaria parasites , 2004, Molecular microbiology.

[62]  D Le Sueur,et al.  An atlas of malaria in Africa. , 1997, Africa health.